Aiforia Technologies Plc, Press Release, December 2, 2024 at 02:00 p.m. EET
Memorial Hospitals Group in Turkey has selected Aiforia Technologies Plc as a partner for AI-assisted pathology image analysis in clinical diagnostics. The collaboration involves the use of Aiforia’s regulatory-approved clinical AI solutions for the analysis of tissue samples from breast, prostate, and lung cancer patients at the Memorial Pathology.
“We are proud to be the first pathology lab in Turkey with full digital workflow and fully digitized for biopsies. Next step was to include clinical AI use, and now we are happy to reach this level with Aiforia. We will use Aiforia’s AI models for prostate, breast and lung carcinoma patients and they will assist us in our diagnostic path. We are happy that we can offer the most innovative and comprehensive diagnostic tools to our patients. We will expand our scope and tools with further collaborations in other disease groups in future,” says Dr. İlknur Turkmen, Director of Pathology at Memorial Hospital Group.
“We are excited to support Memorial Pathology on their journey towards bringing the benefits of AI-powered diagnostics to their pathology practice. We are confident that our clinical solutions will meet the needs of pathologists, improving diagnostic confidence and workflow efficiency, enabling them to deliver even better care to their patients,” says Jukka Tapaninen, CEO of Aiforia.
Memorial Hospital Group is the largest private hospital group in Turkey, serving 75 thousand patients from more than 167 countries annually with 11 hospitals, two medical centers, and one wellness center in five Turkish cities.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com
Back to all blog posts
